DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced the peer-reviewed ...

forming the theoretical basis for many of the acute stroke therapies under study (Lees et al., 2006) as well as the rationale for intervening within a therapeutic time window following ischemic ...

The following is a summary of “Association between impaired brachial flow-mediated dilation and early neurological ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the election of Daniel J. O’Connor to its ...

You will be redirected to our submission process. In the field of cerebrovascular disorders, the management of acute ischemic stroke, particularly those caused by large vessel occlusion, has been ...

In animal studies of acute stroke, bradykinin B2 receptor expression on brain endothelial cells in the ischemic region increased 36-fold. In this environment, newly generated bradykinin from DM199 ...

Hospital-based researchers from Denmark have reported a substantial increase in cardiovascular disease risk among male users ...

DiaMedica Therapeutics (DMAC) announced the peer-reviewed publication entitled: “Recombinant human tissue kallikrein-1 for treating acute ...

The following is a summary of “Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion,” published in the February ...

External control arms, as an integral part of clinical development, present many potential opportunities for sponsors and ...

An update from Diamedica Therapeutics ( ($DMAC) ) is now available. On February 20, 2025, DiaMedica Therapeutics appointed Daniel J. O’Connor to ...

Deadly grip of cardiovascular diseases on Filipino families MANILA, Philippines—Heart attacks and strokes are among the most ...